Cannabis and anxiety: a critical review of the evidence José Alexandre Crippa, Antonio Waldo Zuardi, Rocio Martin-Santos, Sagnik Bhattacharyya, Zerrin Atakan, Philip McGuire and Paolo Fusar-Poli Human Psychopharmacology Clinical and Experimental, 2009, 24, 515-523. Background : Anxiety reactions and panic attacks are the acute symptoms most frequently associated with cannabis use. Understanding the relationship between cannabis and anxiety may clarify the mechanism of action of cannabis and the pathophysiology of anxiety. Aims of the present study were to review the nature of the relationship between cannabis use and anxiety, as well as the possible clinical, diagnostic and causal implications. Method : Systematic review of the [...]
Lire la suiteAge-related differences in the impact of cannabis use on the brain and cognition : a systematic review Claire Gorey, · Lauren Kuhns, · Eleni Smaragdi, · Emese Kroon, · Janna Cousijn European Archives of Psychiatry and Clinical Neuroscience, 2019 https://doi.org/10.1007/s00406-019-00981-7 Abstract The impact of cannabis on the adolescent compared to adult brain is of interest to researchers and society alike. From a theoretical perspective, adolescence represents a period of both risk and resilience to the harms of cannabis use and cannabis use disorders. The aim of this systematic review is to provide a critical examination of the moderating role of age on the relationship between [...]
Lire la suiteRandomized, dose-ranging safety trial of cannabidiol in Dravet syndrome, Orrin Devinsky et al., 2018
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome Orrin Devinsky, Anup D. Patel, Elizabeth A. Thiele, Matthew H. Wong, Richard Appleton, Cynthia L. Harden, Sam Greenwood, Gilmour Morrison, and Kenneth Sommerville, On behalf of the GWPCARE1 Part A Study Group Neurology® 2018, 0:e1-e8. doi:10.1212/WNL.0000000000005254 Abstract Objective : To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. Methods : Patients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial comprised 4-week baseline, 3-week treatment (including titration), 10-day taper, and 4-week follow-up periods. Completers [...]
Lire la suitePsilocybin with psychological support for treatment resistant depression : six-month follow-up R. L. Carhart-Harris, M. Bolstridge, C. M. J. Day, J. Rucker, R. Watts, D. E. Erritzoe, M. Kaelen, B. Giribaldi, M. Bloomfield, S. Pilling, J. A. Rickard, B. Forbes, A. Feilding, D. Taylor, H. V. Curran, D. J. Nutt Psychopharmacology, 2017 https://doi.org/10.1007/s00213-017-4771-x Abstract : Rationale : Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. Objectives : Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. Methods : Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant [...]
Lire la suiteCannabidiol attenuates deficits of visuospatial associative memory induced by D9tetrahydrocannabinol M. Jerry Wright Jr, Sophia A. Vandewater and Michael A. Taffe Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, USA British Journal of Pharmacology, 2013, 170, 1365–1373 BACKGROUND AND PURPOSE Recent human studies suggest that recreational cannabis strains that are relatively high in cannabidiol (CBD) content produce less cognitive impairment than do strains with negligible CBD and similar D9tetrahydrocannabinol (THC) content. Self-selection in such studies means it is impossible to rule out additional variables which may determine both cannabis strain selection and basal cognitive performance level. Controlled laboratory studies can [...]
Lire la suiteNeurobiology of Disease : Daily Marijuana Use Is Not Associated with Brain Morphometric Measures in Adolescents or Adults Barbara J. Weiland, Rachel E. Thayer, Brendan E. Depue, Amithrupa Sabbineni, Angela D. Bryan, and Kent E. Hutchison Department of Psychology and Neuroscience, University of Colorado Boulder, Boulder, Colorado 80309, Department of Psychological and Brain Sciences, University of Louisville, Louisville, Kentucky 40292 The Journal of Neuroscience, 2015, 35, 4, 1505–1512. DOI : 10.1523/JNEUROSCI.2946-14.2015 Abstract : Recent research has suggested that marijuana use is associated with volumetric and shape differences in subcortical structures, including the nucleus accumbens and amygdala, in a dose-dependent fashion. Replication of such results in well controlled [...]
Lire la suiteQu’est-ce que le cannabinol ? Les CBN est le Cannabinoïde responsable d’un meilleur sommeil Aujourd’hui , les capacités de développement et de recherche dans le secteur du cannabis reconnaisse que le facteur responsable du sommeil est le cannabinoïde communément appelé le CBN. Il vous reste quelques fleurs de canna dans une vieille boite ? Certes, il se pourrait qu’il soit beaucoup moins fort en THC. Mais il a de forte chance que votre contenu est chargé en CBN Qu’est ce que le CBN ? Le CBN se forme à partir du THC ” rance ” ou ” pas frais ”. Il a des avantages [...]
Lire la suiteEffective connectivity changes in LSD-induced altered states of consciousness in humans Katrin H. Preller, Adeel Razib, Peter Zeidman, Philipp Stämpflif, Karl J. Friston, and Franz X. Vollenweider Proceedings of the National Academy of Sciences ,· January 2019 DOI: 10.1073/pnas.1815129116 Abstract : Psychedelics exert unique effects on human consciousness. The thalamic filter model suggests that core effects of psychedelics may result from gating deficits, based on a disintegration of information processing within cortico–striato–thalamo-cortical (CSTC) feedback loops. To test this hypothesis, we characterized changes in directed (effective) connectivity between selected CTSC regions after acute administration of lysergic acid diethylamide (LSD), and after pretreatment with Ketanserin (a selective serotonin [...]
Lire la suiteCannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S. Beckley Foundation, 2017. https://beckleyfoundation.org/resource/cannabidiol-inhibits-thc-elicited-paranoid-symptoms-and-hippocampal-dependent-memory-impairment/ Abstract Community-based studies suggest that cannabis products that are high in delta9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment. Healthy participants were [...]
Lire la suiteWhat Is the CBD Dosing Required for Effective Pain Relief ? Damian McNamara, CME, Laurie Barclay, MD Posted: 12/14/2018 Clinical Context The effects of cannabis in humans include euphoria, increased sensitivity to external experience, relaxation, and potential for addiction. Cannabidiol is a compound in the cannabis plant that lacks euphoric and addictive qualities and that may be useful to treat conditions including chronic pain, nausea, epilepsy, psychosis, and anxiety. The optimal therapeutic dose of CBD has not yet been determined, and it has been used in a wide dose range from 2.85 to 50 mg/kg/day. The therapeutic effects of CBD appear to emanate from its interaction [...]
Lire la suite